about
Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta.Low serum urate levels are associated to female gender in multiple sclerosis patients.Geographical variations in sex ratio trends over time in multiple sclerosis.Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study.The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy.Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score.Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group.Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study.Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study.Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort.Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study.Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis.Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients.Variations of the perforin gene in patients with multiple sclerosisThe MoSt Project––More Steps in multiple sclerosis: a Delphi method consensus initiative for the evaluation of mobility management of MS patients in ItalyElevated plasma homocysteine levels in patients with multiple sclerosis are associated with male genderAge-related changes of serum N-acetyl-aspartate in healthy controlsNew natural history of interferon-β-treated relapsing multiple sclerosisItalian Multiple Sclerosis Database NetworkThe Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNβ exposure in multiple sclerosisThe IFNβ treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, ItalyAtypical forms of multiple sclerosis or different phases of a same disease?Age-related disability in multiple sclerosisA cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in ItalyThyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter studyRetrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS RegisterPBMC of Multiple Sclerosis Patients Show Deregulation of OPA1 Processing Associated with Increased ROS and PHB2 Protein LevelsEfficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
P50
Q30817229-F0EB3D8D-3460-4315-AFA7-5BC663192D1FQ34357957-28DF53D8-499F-47E1-B33E-3615D4FEC018Q34469310-4DFA0079-ED37-406A-9F24-DA27B4C82A41Q34527935-D35082CC-8140-49C2-B864-99851AD24FFBQ36070808-914183AF-56FA-4116-A155-0BA88F44FF48Q36226967-3EA5B81E-8988-4649-84ED-4F7653DB2177Q38174450-D78E2DED-66D8-476B-B07E-9712517066F5Q39962881-37054D3F-702D-4B66-83E7-1F23D9FC36E0Q41027362-9AE90419-4CE2-4A06-9B96-A5CF5202EDC3Q42655958-357D4FE2-9C42-42B8-B1A9-D5CEA7667DB0Q43416448-1D6632B0-A3D4-417A-A706-474D4E980692Q43981584-27D9AEAA-358F-479A-A7D1-C742AAF7EC5CQ48740501-004436D4-49AB-4A97-B163-081F1FF13E9EQ48983171-072B0BC8-8A29-4790-906D-A5DED5B6938CQ51810980-4800D905-945E-4E6C-856C-33F53674D813Q52766222-C4EFB682-82C5-43CD-8F84-C1061C9226CAQ59543708-95A01EAC-6A73-4861-AD19-BEF0E154F525Q59649447-F5DC437B-21D8-455E-A25D-52F748C4718AQ59649454-F8533E69-110C-4BCC-A7F4-23997F8E06E9Q59649457-6E80F835-9B6D-4512-9373-D3B82697EC23Q59649484-742521D3-5A6C-43A8-B785-F25FF16C50A2Q59649485-36FEE542-E31D-4495-835B-BC3323D999CEQ59649486-7DF84A15-925E-4790-9B27-AD1A43CB785BQ59649492-819F18A4-330E-44A4-8130-16814E7EA7A4Q59649495-9FAE5971-6059-4578-B1B1-FBB469CFFECBQ59649508-939E649B-0FCF-4477-BCBA-11F99A6BBD38Q63285843-15A2F785-B23D-45AE-BA4D-92AAB44B5E1DQ87269301-13C28431-D5B2-446D-A126-ADA41A330EBDQ90173688-E8B5BB0F-84F4-44F0-95C0-384007FA4F41Q91923716-C3CE1683-2C96-4A86-8B03-96366C454F2DQ92390488-D16B1345-2D00-4774-9BAC-30409D022B8B
P50
description
researcher
@en
name
D Paolicelli
@en
D Paolicelli
@nl
type
label
D Paolicelli
@en
D Paolicelli
@nl
prefLabel
D Paolicelli
@en
D Paolicelli
@nl
P106
P31
P496
0000-0002-8645-1763